The Virginia Risk Sharing Association (VRSA) | Commonwealth of …
WEBVRSA offers comprehensive coverages, resources, and services tailored to meet the unique needs of all Virginia local governments, from the smallest to the largest. Learn More. VRSA for: Cities, Counties, Towns. Water & Wastewater. Schools. Authorities. Why VRSA? Welcome to the Virginia Risk Sharing Association.
Vancomycin-resistant Staphylococcus aureus - Wikipedia
WEBVancomycin-resistant Staphylococcus aureus (VRSA) are strains of Staphylococcus aureus that have acquired resistance to the glycopeptide antibiotic vancomycin. Bacteria can acquire resistant genes either by random mutation or through the transfer of DNA from one bacterium to another.
VISA/VRSA in Healthcare Settings | HAI | CDC
WEBGeneral Information about VISA/VRSA. Visa. Vancomycin [van−kō−mī−sin]-intermediate Staphylococcus aureus [staff−u−lu−kaw−kus aw−ree−us] (also called VISA) and Vancomycin-resistant Staphylococcus aureus (also called VRSA) are specific types of antimicrobial-resistant bacteria.
Vancomycin Resistant Staphylococcus Aureus Infection
WEBApr 2, 2024 · What is vancomycin resistant staphylococcus aureus infection? A vancomycin resistant staphylococcus aureus (VRSA) infection is caused by bacteria. These bacteria are resistant to the antibiotic medicine vancomycin. The infection can spread easily from person to person.
Vancomycin resistant Staphylococcus aureus infections: A …
WEBOct 12, 2019 · The infection caused by methicillin-resistant Staphylococcus aureus (MRSA) is a global threat to public health. Vancomycin remains one of the first-line drugs for the treatment of MRSA infections. However, S. aureus isolates with complete resistance to vancomycin have emerged in recent years.
WEBIf VRSA (vancomycin MIC ≥16 μg/ml) is suspected or confirmed, CDC requests that all VRE, MRSA, and VRSA isolates from the patient be saved to allow characterization of the VRSA precursor organisms. After confirmation of VRSA, these organisms should be shared with public health partners, including CDC.
Infection with Vancomycin-Resistant Staphylococcus aureus …
WEBApr 3, 2003 · In June 2002, a clinical isolate of vancomycin-resistant S. aureus (VRSA) (MIC, >32 μg per milliliter) was identified. 8 In this report, we describe our investigation of this...
UpToDate
WEBVancomycin-resistant Staphylococcus aureus--New York, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:322. Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46:668.
Mechanisms of vancomycin resistance in Staphylococcus aureus
WEBJul 1, 2014 · Reduced vancomycin susceptibility and resistance in methicillin-resistant Staphylococcus aureus. By the end of the 1990s the relatively few multidrug-resistant and highly epidemic clones of methicillin-resistant Staphylococcus aureus (MRSA) had become the most frequent causative agents of S. aureus disease in both hospitals and …
Vancomycin-Resistant Staphylococcus Aureus (VRSA)
WEBVancomycin-resistant Staphylococcus aureus (VRSA) is a type of antimicrobial-resistant bacteria that was first reported in the US in 2002. [2] [3] Vancomycin-intermediate S. aureus (VISA) bacteria are moderately resistant to antibiotics, while VRSA bacteria are strongly resistant to antibiotics. [1] The total number of human VRSA infections to ...
Skip to content